23
GSK ONCOLOGY What Nitro thinks of

What Nitro Thinks: Gsk Oncology

Embed Size (px)

DESCRIPTION

Oncology is an interesting area in digital and I’ve been watching it professionally now for some time. It seems that the difference between the winners and losers is whether you’re pitching a product or not. I’ve been seeing GSKs digital oncology strategy develop for a while and, increasingly, they look a lot like winners. Their recent concentration of all their product sites in to regional hubs will probably pay out some big savings. Their strategy is laser focused on cutting the product site fat and they’re closing the circle by creating a really attractive franchise offering. Couple of points I would have done differently, but otherwise the new site is an excellent step in the right direction.

Citation preview

Page 1: What Nitro Thinks: Gsk Oncology

GSK ONCOLOGY What Nitro thinks of

Page 2: What Nitro Thinks: Gsk Oncology

OVERVIEW

Page 3: What Nitro Thinks: Gsk Oncology

GSK Oncology is a very attractive site.

The site is a big step forward for pharma on the web.

There are good aspects in terms of design,

SEO, CRO, content and value offering.

There are also some interesting learning points.

This is a clearly divided report that aims to give

a balanced view of the site.

Page 4: What Nitro Thinks: Gsk Oncology

GOOD THINGS

Page 5: What Nitro Thinks: Gsk Oncology

Disclaimer

Almost no disclaimer is present on the site.

The disclaimer appears as one line at the top of the page.

GSK.com link is present but not really immediately visible as link

This is likely to reduce the bounce ratio

Page 6: What Nitro Thinks: Gsk Oncology

Functionality The site has a Solid value offering for HCPs

Features include:

Care planner Coming soon

Page 7: What Nitro Thinks: Gsk Oncology

The site is clearly designed. Menus are laid out clearly. The user immediately understands where value is offered.

Clear design

Page 8: What Nitro Thinks: Gsk Oncology

Search Engine Optimisation

GSK have clearly received SEO advice and consultancy on this site.

All the normal features are present.

Clear internal linking is present and 100% of all internal links are followed.

Header tags are present and relevant to the

subject matter.

93.3% of all images have alt tags and can be indexed by Google image search.

Page 9: What Nitro Thinks: Gsk Oncology

Avoiding common design mistakes

No immediately SEO unfriendly design decisions have been made.

The site uses no flash.

And no frames. So most content is

spiderable and search engine friendly.

Page 10: What Nitro Thinks: Gsk Oncology

THINGS THAT COULD IMPROVE

Page 11: What Nitro Thinks: Gsk Oncology

The site has very little content.

The value offering, in terns of literature could be more developed.

The “Contemporary issues page” is mainly

reprints of pre-2009 articles.

Content

Page 12: What Nitro Thinks: Gsk Oncology

The site has very little multimedia.

Video is limited to one talking heads video explaining GSK’s Commitment to Cancer and how they break

new ground in research.

The video is not embedded on the pages where it is referenced.

The user is taken away from the section which they

are reading to view the video.

Media

Page 13: What Nitro Thinks: Gsk Oncology

Social Media • Social sharing is present on the site, but not

emphasised. • The site has no social media linked to it. • The twitter account @gskoncology has been

registered. • The account is registered to “David Arce

Retamal” a pharmaceutical and digital marketing consultant in Santiago Chile.

• It’s only tweet was made on 23/07/09 • Whether or not this indicated their

ownership is unclear.

Social sharing

Page 14: What Nitro Thinks: Gsk Oncology

Up to date content

The site has no functionality indicating that content on any pages will be updated. There is no blog, no news, and no RSS feed. Google prefers sites that are more frequently updated.

Page 15: What Nitro Thinks: Gsk Oncology

Functionality

In spite of the functionality being good there is no new functionality on the site.

The Cancer trials search app has been

previously surveyed in some of our benchmarks.

The events calendar has no content on site and

leads users away from the site.

Page 16: What Nitro Thinks: Gsk Oncology

Mobile optimisation

The site has no mobile optimised

version.

This will become a problem if GSK

attempt an email marketing campaign as these are likely to be read on a mobile

phone.

Page 17: What Nitro Thinks: Gsk Oncology

THINGS TO WATCH

Page 18: What Nitro Thinks: Gsk Oncology

Statistics Currently the site has no clear metrics available

from public sources.

The site is still nascent and therefore should be watched for its success.

SEO Moz has not crawled the site properly since it

had a 302 temporary redirect to gskcares.com

Page 19: What Nitro Thinks: Gsk Oncology

Structure

The sitemap of the site is held in a /HCP folder.

This is a possible indication that there is a patient sections in development.

Page 20: What Nitro Thinks: Gsk Oncology

Meta keywords

Meta keywords are not generally used by anyone and are ignored by search engines.

These serve to give us an indication of the

keywords that they are targeting.

Page 21: What Nitro Thinks: Gsk Oncology

CONCLUSION

Page 22: What Nitro Thinks: Gsk Oncology

This site is still nascent.

It will be exciting to see how it will develop and what campaigns they will run for the any

new content that they release.

Ultimately, the test of success is popularity, but the indications show that HCPs are likely to revisit the site. Should they update their content update their offering will be strong.

Page 23: What Nitro Thinks: Gsk Oncology

THANK YOU FOR YOUR KIND ATTENTION

Contact: Dan Winkler Business Analyst address 13/ 14 Archer Street, London, W1D 7BD website www.nitro-digital.co.uk

telephone +44 (0) 20 7148 6825 mobile +44 (0) 7912 275 066 email [email protected]